Skip to content

Coherence Breathing Before Cardiopulmonary Exercise Testing

Acute Effects of Coherence Breathing on Cardiopulmonary Exercise Responses in Recreationally Active Adults: A Randomized Crossover Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07650279
Enrollment
20
Registered
2026-06-16
Start date
2026-06-11
Completion date
2026-10-06
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breathing Rate

Keywords

heart rate variability, breathing, exercise testing, heart rate recovery, warm-up, slow paced breathing

Brief summary

This randomized crossover trial will examine the acute effects of pre-exercise coherence breathing on cardiopulmonary exercise responses in recreationally active adults. Participants will complete two experimental conditions in randomized order: 5 minutes of guided coherence breathing and 5 minutes of quiet seated spontaneous breathing. Following each condition, participants will perform a standardized treadmill warm-up and a maximal cardiopulmonary exercise test. Outcomes will include oxygen consumption, heart rate, heart rate recovery, perceived exertion, time to completion, and heart rate variability. The findings may help determine whether coherence breathing can serve as an effective autonomic priming strategy before a bout of maximal exercise

Detailed description

Slow-paced breathing performed at approximately six breaths per minute has been shown to influence autonomic nervous system activity and heart rate variability. Coherence breathing may improve physiological regulation by enhancing cardiorespiratory synchronization and vagal modulation. However, little is known about whether a brief bout of coherence breathing performed immediately before exercise can influence cardiopulmonary exercise performance. The purpose of this study is to investigate the acute effects of pre-exercise coherence breathing on cardiopulmonary exercise performance and autonomic responses in recreationally active adults. This study will utilize a randomized, counterbalanced crossover design. Recreationally active adults aged 19 to 45 years will complete two experimental conditions in random order separated by a minimum of 48 hours (maximum of 7 days). In one condition, participants will perform 5 minutes of guided coherence breathing using a visual breathing pacer at approximately 6 breaths per minute while seated. In the comparison condition, participants will sit quietly for 5 minutes with spontaneous breathing. Following each condition, participants will complete a standardized treadmill warm-up and a maximal cardiopulmonary exercise test (CPET). Heart rate variability will be assessed during baseline seated rest and during the breathing intervention. Cardiopulmonary variables collected during CPET will include oxygen consumption, heart rate, respiratory responses, and ratings of perceived exertion. Recovery responses over 5 minutes seated include heart rate and blood pressure will also be assessed following exercise. Findings from this study may improve our understanding of breathing strategies for athletic performance. Specifically, whether slow paced breathing through coherence breathing can serve as a practical autonomic priming strategy before maximal exercise. Moreover, insights from this study may provide insight into the acute interaction between breathing regulation, autonomic function, and exercise responses.

Interventions

BEHAVIORALCoherence Breathing

Participants complete 5 minutes of guided coherence breathing which consists or around 6 breathing cycles (5 seconds inhale and 5 seconds exhale)

Participants sit quietly for 5 minutes with their regular spontaneous breathing

Sponsors

Human Performance Lab of Monmouth University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults aged 19 to 45 years. * Any biological sex. * Recreationally active, defined as accumulating at least 3 hours per week of moderate-to-vigorous physical activity. * Able to perform maximal cardiopulmonary exercise testing on a treadmill. * Able to provide informed consent. * Cleared for moderate-to-vigorous physical activity based on the PAR-Q+ (or PAR-Q 2023).

Exclusion criteria

* Accumulate less than 3 hours per week of moderate-to-vigorous physical activity. * Presence of a health condition that contraindicates maximal exercise testing, including: Cardiovascular disease. Pulmonary disease. Metabolic disorders. Neuromuscular disorders. Orthopedic limitations that impair exercise performance. * Acute illness that would interfere with participation or exercise testing. * Inability or unwillingness to complete study procedures. * Inability or unwillingness to provide informed consent. * Not cleared for moderate-to-vigorous physical activity based on the PAR-Q+ (or PAR-Q+ 2023).

Design outcomes

Primary

MeasureTime frameDescription
Peak Oxygen consumptionduring each maximal exercise test immediately after the breathing conditionPeak oxygen consumption measured during the maximal cardiopulmonary exercise test (CPET) using a portable metabolic analyzer (Vo2 Master)

Secondary

MeasureTime frameDescription
rating of perceived exertion (RPE)measured at baseline, during the exercise test and after recoveryusing the RPE borg scale (from 1-10)
Heart Rate Recoverydifference between peak HR during CPET and HR at minute 1, minute 2 and minute 5 of recovery.Heart Rate (bpm) immediately after completing the CPET over a period of 5 minutes
Time to completion of maximal exercise testduring the exercise testtotal duration of the exercise test since test starts to voluntary termination
Peak Heart Ratemeasured during the maximal exercise testmaximal heart rate achieved during the maximal exercise test

Countries

United States

Contacts

CONTACTTamara Rial-Faigenbaum, PhD
trialfai@monmouth.edu2159878984
CONTACTJaime Pigman, PhD
jpigman@monmouth.edu732-749-0160

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026